23,800 Shares in Cellectar Biosciences, Inc. (NASDAQ:CLRB) Acquired by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC acquired a new stake in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 23,800 shares of the biopharmaceutical company’s stock, valued at approximately $51,000.

Other hedge funds have also added to or reduced their stakes in the company. XTX Topco Ltd increased its holdings in shares of Cellectar Biosciences by 432.4% during the second quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 51,413 shares in the last quarter. Vanguard Group Inc. boosted its stake in Cellectar Biosciences by 146.7% in the 1st quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock worth $4,741,000 after purchasing an additional 708,191 shares in the last quarter. Rosalind Advisors Inc. grew its position in Cellectar Biosciences by 335.4% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,705,616 shares of the biopharmaceutical company’s stock valued at $6,764,000 after purchasing an additional 2,084,138 shares during the last quarter. Finally, AIGH Capital Management LLC increased its stake in Cellectar Biosciences by 8.2% during the 2nd quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock valued at $7,590,000 after purchasing an additional 231,270 shares in the last quarter. 16.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Oppenheimer reiterated an “outperform” rating and issued a $14.00 target price on shares of Cellectar Biosciences in a research note on Friday, October 11th. StockNews.com raised Cellectar Biosciences to a “sell” rating in a research report on Thursday, September 26th.

Cellectar Biosciences Stock Performance

NASDAQ CLRB opened at $2.05 on Thursday. Cellectar Biosciences, Inc. has a one year low of $1.82 and a one year high of $4.45. The stock has a 50-day moving average of $2.10 and a 200 day moving average of $2.52. The company has a market capitalization of $73.49 million, a price-to-earnings ratio of -0.67 and a beta of 0.99.

Cellectar Biosciences Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.